Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to 7.71%.

  • Angiodynamics' EBITDA Margin rose 75200.0% to 7.71% in Q4 2025 from the same period last year, while for Nov 2025 it was 10.59%, marking a year-over-year increase of 726700.0%. This contributed to the annual value of 13.66% for FY2025, which is 496600.0% up from last year.
  • As of Q4 2025, Angiodynamics' EBITDA Margin stood at 7.71%, which was up 75200.0% from 14.07% recorded in Q3 2025.
  • Angiodynamics' 5-year EBITDA Margin high stood at 44.52% for Q3 2023, and its period low was 265.88% during Q1 2024.
  • For the 5-year period, Angiodynamics' EBITDA Margin averaged around 23.25%, with its median value being 12.47% (2021).
  • As far as peak fluctuations go, Angiodynamics' EBITDA Margin plummeted by -2548200bps in 2024, and later skyrocketed by 2520300bps in 2025.
  • Over the past 5 years, Angiodynamics' EBITDA Margin (Quarter) stood at 11.09% in 2021, then increased by 14bps to 9.5% in 2022, then tumbled by -75bps to 16.59% in 2023, then grew by 8bps to 15.23% in 2024, then surged by 49bps to 7.71% in 2025.
  • Its EBITDA Margin stands at 7.71% for Q4 2025, versus 14.07% for Q3 2025 and 7.22% for Q2 2025.